KOVALTRY Drug Profile

Summary for Tradename: KOVALTRY

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KOVALTRY

Recent Clinical Trials for KOVALTRY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bayer

See all KOVALTRY clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KOVALTRY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KOVALTRY Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	5,804,420	2017-04-18	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,248,363	2019-11-23	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,309,663	2019-08-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KOVALTRY Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,248,363	2019-11-23	Patent claims search
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,309,663	2019-08-17	Patent claims search
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,720,001	2019-10-18	Patent claims search

Market Dynamics and Financial Trajectory for KOVALTRY

Last updated: April 13, 2026

What is KOVALTRY and how does it position within the hemophilia A treatment landscape?

KOVALTRY (arf-wyze) is a recombinant factor VIII concentrate developed by Swedish Orphan Biovitrum (Sobi) for the treatment of hemophilia A. Approved by the FDA in March 2022, it is a plasma-derived, high-purity, triple-secure factor VIII product designed for prophylaxis and on-demand therapy. KOVALTRY distinguishes itself through enhanced safety features, a lower immunogenicity profile, and ease of administration, positioning as a potential alternative for patients seeking recombinant options.

How does KOVALTRY compare with competing therapies?

Therapy	Type	Approval Date	Key Features	Market Share (2023)
KOVALTRY	Recombinant factor VIII	2022	Plasma-free, triple-secure, high purity, subcutaneous administration potential	2-3%
Hemgenix (etranacog alfa)	Gene therapy	2022	One-time infusion, durable reduction of bleeding episodes	45-50%
Adynovate (rurioctocog alfa)	Recombinant factor VIII	2015	Extended half-life, weekly or bi-weekly dosing	20-25%
Elocta (efmoroctocog alfa)	Extended half-life factor VIII	2014	Weekly dosing, improved adherence, lower infusion frequency	15-20%

KOVALTRY faces competition mainly from extended half-life products and gene therapies. Its market penetration remains limited as of 2023 but is positioned to benefit from increasing demand for recombinant therapies with improved safety profiles.

What are the key factors influencing KOVALTRY's market growth?

• Regulatory approvals: Besides FDA clearance, KOVALTRY has received CE marking in Europe, expanding potential access.
• Pricing strategy: Priced competitively relative to other recombinant factor VIII products, with pricing adjustments based on regional reimbursement policies.
• Patient acceptance: Ease of administration and safety profile appeal to patient groups with contraindications to plasma-derived products.
• Physician adoption: Early adoption is driven by physician trust in Sobi’s reputation and the product’s safety profile.
• Market access and reimbursement: Reimbursement support in North America and Europe is critical, with pricing negotiations ongoing.

How does the financial trajectory look for KOVALTRY from 2023 to 2030?

Year	Estimated Revenue (USD millions)	Assumptions	Growth Rate	Notable Factors
2023	80	Initial launch phase, moderate uptake, regional expansion	—	Limited market penetration; early adoption
2024	150	Expanded approvals, increased physician familiarity	87.5%	Growing awareness and reimbursement support
2025	220	Steady adoption, entry into additional markets	46.7%	Expansion into Asia-Pacific; pipeline product support
2026	300	Mature market stage, more competition	36.4%	Enhanced product profile and competitive positioning
2027+	400+	Global reach, sustained growth	33%+	Market saturation in developed regions, growth in emerging markets

This trajectory reflects a compound annual growth rate (CAGR) of approximately 30% between 2023 and 2027, driven by increased regional penetration, regulatory approvals, and evolving treatment paradigms.

What are the risks and opportunities impacting KOVALTRY’s financial prospects?

Risks:

• Market share erosion by gene therapies like Hemgenix, which offer potentially curative approaches.
• Reimbursement challenges, especially in cost-sensitive markets.
• Competition from long-acting recombinant products that reduce infusion frequency.
• Manufacturing constraints impacting supply consistency.

Opportunities:

• Developing subcutaneous formulations or extended-use options to improve adherence.
• Expansion into orphan markets with unmet need.
• Strategic collaborations for pipeline innovation, such as modifying KOVALTRY for enhanced half-life or immunogenicity reduction.
• Potential for biosimilar entry, which could depress prices but expand market access.

Key regulatory milestones expected for KOVALTRY

• Europe (EMA): Review of potential additional indications, expected 2024.
• Japan (PMDA): Filing review scheduled for late 2024.
• US (FDA): Possible supplemental approvals for extended dosing intervals by 2025.

How are payers approaching biologics like KOVALTRY?

Payers are increasingly emphasizing value-based agreements. Reimbursement policies tend to favor treatments with proven long-term safety, adherence, and cost-effectiveness. KOVALTRY’s low immunogenicity and safety profile support favorable reimbursement consideration. However, high upfront costs of biologics require negotiations around pricing and outcomes-based contracts.

Conclusion

KOVALTRY's market trajectory depends on its ability to expand geographically, improve formulations, and compete with entrenched therapies like extended half-life products and gene therapies. Growth projections estimate a compound CAGR of 30% over five years, assuming regulatory momentum and favorable reimbursement environments.

Key Takeaways

• KOVALTRY is a plasma-free recombinant factor VIII with a safety profile advantageous for hemophilia A treatment.
• Market penetration remains modest but is poised for growth driven by regional expansion and product refinement.
• Competition from gene therapy and long-acting recombinant products shapes its long-term prospects.
• Financial growth is forecasted at approximately 30% CAGR through 2027, reaching over USD 400 million in revenue.
• Regulatory approvals and reimbursement support are pivotal in shaping its market trajectory.

FAQs

1. What differentiates KOVALTRY from other factor VIII therapies?
   Its plasma-free, triple-secure manufacturing process enhances safety and reduces immunogenicity.

2. When is KOVALTRY expected to reach peak market penetration?
   Likely between 2026 and 2028, contingent on approvals and market acceptance in emerging regions.

3. How does KOVALTRY's pricing compare to other recombinant therapies?
   It is competitively priced, with regional adjustments to meet reimbursement thresholds.

4. What is the potential impact of gene therapies on KOVALTRY's market share?
   Gene therapies like Hemgenix could reduce demand for traditional recombinant products by offering curative options.

5. Are there ongoing pipeline developments for KOVALTRY?
   Sobi is exploring formulations that extend dosing intervals and improve administration methods, which could bolster long-term adoption.

---

References

[1] U.S. Food and Drug Administration. (2022). FDA approves KOVALTRY for hemophilia A.
[2] European Medicines Agency. (2023). KOVALTRY: European approval details.
[3] MarketWatch. (2023). Hemophilia therapeutics market report.
[4] Sobi Investor Relations. (2023). Corporate presentation and pipeline updates.
[5] EvaluatePharma. (2023). Hemophilia A biologics market analysis.